- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20:26 | AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal | ||
| 17:26 | Indivior warns of 'significant impact' on R&D team after opioid use disorder drug fails phase 2 | ||
| 16:26 | BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific | ||
| 15:26 | Leo Pharma pays $50M for Replay and its preclinical skin disease gene therapy | ||
| 14:26 | BeOne signs $2B deal for option on preclinical trispecific antibody from China's Huahui | ||
| 11:26 | GSK's $700M Alector bet blows up as Alzheimer's drug flunks phase 2 | ||
| 10:26 | Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs | ||
| 09:26 | AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M | ||
| Mi | FDA hits Newron's phase 3 schizophrenia trial with clinical hold in US after patient death | ||
| Mi | AstraZeneca restarts £300M investment in UK, but Merck not budging | ||
| Mi | Teva inks $700M Emalex buyout to bag near-approval Tourette drug | ||
| Mi | AstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial | ||
| Mi | Which blockbuster is GSK gunning for next? CEO Miels is looking to oncology | ||
| Mi | GSK walks away from $100M bet on Mersana's STING ADC, pauses mRNA bird flu shot program | ||
| Di | FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board | ||
| Di | Protagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits | ||
| Di | AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition | ||
| Di | Incyte's JAK inhibitor scores phase 3 vitiligo wins but can't quite shake off Rinvoq | ||
| Di | Erasca hits 'home run' with cancer data as analyst suggests stock drop prompted by patient death | ||
| Di | Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing | ||
| Di | Boehringer links dual agonist to 16.6% weight loss in phase 3, but leaves key questions unanswered | ||
| Di | Novartis CEO 'continuing to evaluate' in vivo CAR-Ts, but no deals in the works | ||
| Mo | Seaport, Hemab chart courses for $180M IPOs to fund depression, clotting candidates | ||
| Mo | Compass Therapeutics' stock heads south after cancer bispecific misses on overall survival | ||
| Mo | Astellas thins early pipeline, swaps out struggling rare disease gene therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.